| 3i 3i brings capital, knowledge and connections to the creation and development of businesses around the world. It invests in a wide range of opportunities from start-ups to buy-outs and buy-ins, focusing on businesses with high growth potential and strong management. 3i invests in businesses across three continents through local investment teams in Europe, Asia Pacific and the USA. To date, 3i has invested over £14.5 billion (including co-investment funds). In the 12 months to 31 March 2002, an average of £4.1 million (including co-investment funds) was invested each working day. In the 12 months to 31 March, 3i invested £548m (including co-investment funds) in 361 technology businesses. 3i makes technology investments in a broad range of sectors including Communications, Healthcare and Software & Internet. The portfolio includes businesses at all stages of development. At 31 March 2002, 3i's technology portfolio was valued at £1.7 billion and included over 800 businesses, thereof 25% healthcare. 3i started in the mid 80ies with first investments in healthcare by supporting first wave companies such as Shire, Chiroscience and Oxford Asymmetry. Today, the European healthcare portfolio comprises approximately 180 companies. |
 |
| Apax
Partners Apax Partners is one of the world's leading private equity investment groups dedicated to high performance, entrepreneurial businesses. The group advises a number of Investment Pools with an accumulated total of € 12 billion and pursues a balanced equity portfolio strategy, investing in companies at all stages of development from start-up to buy-out. The group focuses primarily on six industry sectors: Telecommunications, Information Technologies, Media, Healthcare & Biotechnologies, Retail & Consumer Products and Financial Services. Founded in 1972 in the United States and in Europe, Apax Partners currently has eleven offices worldwide. For further information on Apax Partners, visit www.apax.com. |
 |
| Atlas
Venture Atlas Venture is the leading international early-stage venture capital firm, investing in communications, information technology and life sciences companies. Atlas Venture has investing offices in Boston, London, Munich and Paris, and its investments are evenly divided between the United States and Europe. Founded in 1980, Atlas Venture has organized six international funds, and currently manages more than $2.1 billion in committed capital. The Atlas Venture investment team is comprised of seasoned operating executives and career venture capitalists that have been deeply involved in the formation and development of more than 300 companies worldwide. In 2000, our portfolio completed 14 IPOs and 11 acquisitions. Recent Atlas Venture portfolio company IPOs include Actelion (SWX: ATLN), deCODE genetics (Nasdaq: DCGN), Exelixis (Nasdaq: EXEL),Novus Pharma (Cell Therapeutics Inc.), Orchestream Ltd (LSE: OCH), SpeechWorks International (Nasdaq: SPWX) and Variagenics (Nasdaq: VGNX). Recent acquisitions of Atlas Venture portfolio companies include Cerulean Technology (Aether Systems), eRoom Technology (Documentum), eGroups (Yahoo!), Element 14 (Broadcom), OnDisplay (Vignette), Trading Dynamics (Ariba), Omnia Communications (CIENA), Revit Technolgies (Autodesk), RightPoint Software (E.piphany), Systemonic (Philips), and T.sqware (GlobeSpan). |
 |
|
Aventis Aventis is a world leader in the discovery, development and marketing of innovative pharmaceutical products. We aim to create and sustain value by being recognized as a pharmaceutical industry leader – valued by patients and healthcare providers, sought after as an employer, and respected by the scientific community and by our competitors. Our core business comprises activities in prescription drugs and human vaccines as well as the 50% equity interest in the animal health business Merial, a 50-50 joint venture with Merck & Co. In 2002, core business sales were € 17.59 billion. In 2002, our research and development spending totaled € 3.14 billion or 17.9% of our core business sales. Our R&D efforts are focused on delivering innovations for therapeutic areas such as respiratory/allergy, cardiovascular disease, oncology, diabetes and human vaccines. We currently have more than 40 compounds in clinical development, including over 25 in early-stage clinical development and more than 15 in late-stage development. By taking early data-driven decisions, we want to optimize and prioritize our compound portfolio so as to increase the success potential and thus the value of our pipeline. In addition, we are actively pursuing attractive in-licensing opportunities and alliances to strengthen our leading positions in disease areas such as oncology, diabetes, thrombosis and vaccines. Aventis was formed in 1999 by the business combination of Hoechst AG and Rhône-Poulenc S.A. – two companies with rich histories spanning over 100 years and experience in markets throughout the world. Outstanding research accomplishments, major products and renowned brand names have given Aventis a strong foundation for a successful future. |
| AstraZeneca AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $18 billion. AstraZeneca provides new, effective medicines designed to fight disease in areas of high medical need including cancer, cardiovascular, CNS, GI, infection, pain control and respiratory. It has a powerful product portfolio with many world leading products in their sectors. AstraZeneca has active worldwide sales in over 100 countries and manufacturing in 20 with in total around 58,000 employees worldwide. AstraZeneca combines global capabilities with high quality relationships in local markets. It aims to use its leading position in many important areas of healthcare to make a difference to the lives of patients and the healthcare providers who treat them. AstraZeneca has an annual R & D spend of over $3 billion and employs over 10,000 people in R & D with major centres in 5 countries. It has a strong R & D pipeline with a number of significant innovations. AstraZeneca is committed to continued innovation including a focus on partnering, close customer relations, people development and a responsible approach to business. |
| BankInvest
Bio Venture BankInvest was established as a mutual fund in 1969 by a number of local and regional banks, and today's owners represent a total balance of more than 35bn euros. With more than 30 years' experience as an asset management company and with more than 100,000 unit holders, institutional investors and corporations as clients, BankInvest is at present Denmark's third largest mutual fund manager and advisor. In June 2001, BankInvest's assets under management amounted to approximately 5bn euros, and these continue to grow extremely strongly. BankInvest manages portfolios of both bonds and equities. By using a selective investment strategy, BankInvest manages portfolios with focus on geographic areas as well as sector-specific portfolios. It is particularly within the fields of complex investments, e.g. biotechnology, information technology and emerging markets, that BankInvest distinguishes itself as an internationally leading asset management group. In the field of venture capital, BankInvest is also one of the leading venture capital providers in Denmark within the growth areas of biotechnology and information technology. |
 |
|
Bayern
Kapital GmbH Bayern Kapital GmbH is a Bavarian Venture Capital Company, founded in 1995 at the initiative of the Bavarian State Government and headquartered in Landshut, Germany. Its main objective is to provide venture capital to emerging technology-oriented companies in close cooperation with private venture capitalists, business angels or other institutional investors in an effort to enable promising small and mid-sized enterprises making use of Bavaria’s strong economic and scientific infrastructure. Bayern Kapital was founded as a subsidiary of Bavaria’s Development Bank LfA Förderbank Bayern (LfA) and initially vested with operational capital of EUR 31 million. Due to attractive investment terms and conditions, enabling investments mainly in the form of a silent partnership, Bayern Kapital’s investment scheme was widely accepted by company founders and the VC community. In 1998 an additional fund of EUR 78 million - Technologie Beteiligungsfonds Bayern GmbH & Co KG (Technofonds Bayern I)- set up by LfA and tgb and managed by Bayern Kapital as General Partner, was established. In just a few years, Bayern Kapital has used these two original funds to finance over 100 promising Bavarian start-ups, many of which have been able to achieve good market positions with excellent prospects. By financing numerous Bavarian biotech companies, Bayern Kapital has also made a significant contribution to developing and establishing the biotech sector in Bavaria. In order to ensure continued innovation and growth in Bavaria’s early stage financing, Bayern Kapital recently raised two new funds. Bayern Kapital, as managing partner, joined forces with LfA and tbg to create Seedfonds Bayern GmbH & Co KG (Seedfonds Bayern) as a seed funding vehicle with a volume of EUR 22 million for financing start-ups in the medical technology, environmental technology and information/communication/software sectors. Seedfonds Bayern usually invests up to EUR 150,000 per company. The close cooperation between Seedfonds Bayern and tbg can result in this sum being increased to up to EUR 300,000 within the scope of a joint seed phase investment. Technologie Beteiligungsfonds Bayern II GmbH & Co KG (Technofonds Bayern II) with an initial volume of EUR 60 million and a target volume of EUR 75 million was set up with the same partners plus the European Investment Bank. Although concentrating on early stage investments Technofonds Bayern II can also fund later stage projects. Its main purpose is to facilitate access to venture capital for emerging Bavarian firms planning, developing and introducing new products. Technofonds Bayern II invests up to EUR 1 million per target company in the form of a silent partnership combined with a share in equity. Bayern Kapital Risikokapitalbeteiligungs
GmbH |
 |
| Boehringer
Ingelheim We are a globally operating, independent corporation committed to researching, manufacturing and marketing drugs for human and veterinary medicine. For more than 100 years, our goal has been to secure and maintain our independence by means of continuous growth. The Boehringer Ingelheim Corporation, with 156 subsidiaries in 44 countries across the world and a total of around 32,000 employees, is one of the world's 20 leading pharmaceutical companies.With its activities focused on Human Pharmaceuticals and Animal Health, Boehringer Ingelheim posted net sales of almost 7.6 billion euro in 2002. A family-owned company founded in 1885 and headquartered in Ingelheim am Rhein, Boehringer Ingelheim can look back on a long history of successful pharmaceutical innovations and product launches. In the business year 2002, Boehringer Ingelheim spent more than 1.3 billion euro on research and development, about one fifth of net sales in its largest business segment Prescription Medicines. The company's research and development activities and production and distribution centres are spread across the entire globe. |
| Cyclacel Cyclacel Limited is a biopharmaceutical company that designs and develops small molecule drugs that act on key cell cycle regulators to stop uncontrolled cell division in cancer and other diseases involving abnormal cell proliferation. The Company’s discovery engines integrate core cell cycle expertise with a large library of proprietary gene-based targets, state-of-the-art molecular biology, RNAi functional genomics, computational chemistry and biomarker technology to rapidly deliver new drug candidates. Cyclacel has five research and development programmes currently underway. Most advanced is CYC202, a Cyclin Dependent Kinase (CDK) inhibitor, currently in Phase IIa trials for cancer. CYC202 has also completed a Phase I trial in healthy volunteers and is being explored for use in glomerulonephritis, a disease of renal cell proliferation. |
| DVC
Deutsche Venture Capital DVC Deutsche Venture Capital is an early-stage VC-fund, based in Munich, which is focused on European technology and life sciences companies. In< life sciences, DVC particularly looks for opportunities in therapeutic and< diagnostic product development as well as for platform technologies and medical devices. In technologies, we focus on information, communication and industrial technologies (ICI). DVC has 300 million Euro capital under management. For investments in private companies, we invest approximately 1 - 10 million Euro as a lead or co-lead-investor also in larger rounds. DVC is a "value-add" financial investor. Each sector team consists of experienced investment managers with relevant backgrounds. Since its formation in 1998, DVC has invested in ap-proximately 50 companies. Decisive criteria for the success of a venture are the unique position of a project or technology, the experiences of the management team and the target- and market-oriented business model. DVC can provide the following: DVC Deutsche Venture Capital |
 |
| Earlybird
GmbH & Co. KG Earlybird provides capital, know-how, management support and a large network of industry experts to selected European and North American new technology enterprises and innovative entrepreneurs. Its strategy is to be among the first venture investors in technology companies that seek to create new markets. Earlybird currently manages three funds totalling US $ / Euro 300 million in committed capital. Its investment focus lies on information technology, communications, healthcare and convergent technologies. With offices in Europe (Hamburg, Munich) and the US (Palo Alto), Earlybird is well positioned to take advantage of international opportunities and to assist its portfolio companies to gain access to the international market place and financial resources. Earlybird´s investment professionals have extensive finance and start-up operating experience and actively support portfolio companies. In addition, a network of experienced industry specialists serves on the advisory board and assists Earlybird and its portfolio companies in providing strategic advice and operational support. |
 |
| Genzyme
GmbH Genzyme Corporation is a global biotechnology company dedicated to making a major positive impact on the lives of people with serious diseases. The company’s broad product portfolio is focused on rare genetic disorders, renal disease, and osteoarthritis, and includes an industry-leading array of diagnostic products and services. Genzyme’s commitment to innovation continues today with research into novel approaches to cancer, heart disease, and other areas of unmet medical need. Genzyme’s 5,300 employees worldwide serve patients in more than 80 countries. |
| GlaxoSmithKline The Company GSK’s mission is to improve the quality of human life by enabling people to do more, feel better and live longer. Headquartered in the UK with operations based in the US, GSK is one of the industry leaders with an estimated seven per cent of the world’s pharmaceutical market. GSK has leadership in four major therapeutic areas: anti-infectives, central nervous system, respiratory and gastro-intestinal/metabolic. In addition, it is a leader in the important area of vaccines. The company also has a Consumer Healthcare portfolio comprising over-the-counter medicines, oral care products and nutritional healthcare drinks, all of which are among the market leaders. GSK has 100,000 employees worldwide. Of these, over 40,000 are in sales and marketing, the largest sales force in the industry. More than 42,000 employees work at manufacturing sites in 40 countries, and over 16,000 are in R&D. GSK was formed in December 2000 from a merger between SmithKline Beecham and Glaxo Wellcome. Collaborative Interests GSK Ventures |
 |
| HBM
Partners AG HBM BioVentures Ltd is a holding company established under Swiss law, domiciled in Baar, Switzerland. The Company invests primarily in later-stage private equity, but also in public companies in the biotechnology, emerging pharma, medical technology and related industries. Portfolio companies are located mainly in Western Europe and the U.S. While most investments are made in companies directly, some take place through specialised, regionally active venture capital funds. Within its industrial scope, HBM BioVentures offers institutional and private investors an ideal opportunity to invest in a broadly diversified portfolio combining private and public companies. HBM BioVentures is independent and due to its legal structure can implement innovative financial transactions. The portfolio is professionally managed by experienced specialists and combines high transparency with an advantageous tax structure. |
| Israel
Seed Partners Israel Seed Partners (ISP) is Israel's leading venture capital fund specializing in early stage investments. Founded in 1995 by Neil Cohen and Jon Medved with initial capital of just $2 million, ISP now has close to $300 million under management and has invested in more than 50 companies, including Compugen (NASDAQ: CGEN), DealTime, XaCCt, Chiaro Networks, Finjan Software and Qlusters. Each of ISP's three partners (Michael Eisenberg has joined ISP since its inception) focus on their own areas of expertise which include fiber optic and wireless communications systems, internet infrastructure, enterprise software and life sciences. Israel Seed Partners is backed by prestigious institutional and corporate investors including Horsley Bridge, MIT, CommonFund Capital, AOL Time Warner, IBM, AXA, Broadview, Silicon Valley Bank, Horsley Bridge and Flag Venture Management. |
| MPM
Capital MPM Capital is the world's largest dedicated investor in life sciences. With committed capital under active management of more than $2.1 billion, MPM is uniquely structured to invest globally in healthcare innovation. In addition to its BioVentures family of venture capital funds, MPM invests in the public markets through its BioEquities hedge fund. Primarily in biotechnology, but also in medical devices and biopharmaceuticals, MPM has seamlessly integrated private and public equity products to target innovation in healthcare and, thereby, deliver exceptional returns to investors. The MPM BioVentures and MPM BioEquities family of funds are two distinctly different but highly complementary investment vehicles. |
| Merlin
Biosciences Limited Merlin Biosciences is a specialised venture investor in life sciences companies. It makes equity investments on behalf of its investment partnerships. Since 1997, Merlin has invested in 26 European biotechnology companies. It is raising its third investment partnership, the Merlin Biosciences Fund III, L.P., and advises funds with €400 million of equity capital. It has a world-wide, loyal network of advisers and experienced strategic partners. Merlin invests in companies that are bringing to market human medicines or medical devices with groundbreaking technology and great commercial potential. It has a reputation as an attractive partner for management teams who can create substantial value for investors. |
| Novartis
Pharma, AG Novartis (NYSE: NVS) is a world leader in healthcare with core businesses in pharmaceuticals, consumer health, generics, eye-care, and animal health. In 2001, the Group’s businesses achieved sales of CHF 32.0 billion (USD 19.1 billion) and a net income of CHF 7.0 billion (USD 4.2 billion). The Group invested approximately CHF 4.2 billion (USD 2.5 billion) in R&D. Headquartered in Basel, Switzerland, Novartis employs about 72,600 people and operates in over 140 countries around the world. |
 |
|
Polaris Venture Partners Business Focus: Polaris Venture Partners is an early stage venture capital firm with two locations in the U.S.: Boston, Massachusetts, and Seattle, Washington. Polaris currently has over $2.0 billion under management with investments in more than 50 diversified information technology and life sciences companies. Through its philosophy of active lead investing and partnering with early and revenue stage companies, the firm’s team of experienced venture investors and technology executives has generated triple-digit returns from investments across its four funds. Target Markets Polaris invests two-thirds of its capital in information technology and one-third in life sciences companies. Within the information technology sector, Polaris has invested in companies with expertise in Internet infrastructure, e-commerce, telephony, and network hardware and software. In the life sciences sector, the firm has invested in companies focused on medical devices, pharmaceuticals, genomics, and health care services. Portfolio Clients: Polaris Venture Partners has more than 50 companies in its portfolio, including industry leaders such as Akamai Technologies, Allaire Corporation, Avici, deCODE Genetics, and Paradigm Genetics. Leadership: Polaris Venture Partners is led by four managing general partners: Steve Arnold, Jonathan Flint, Terry McGuire, and Alan Spoon. There are also six general partners, two venture partners, one executive in residence, one entrepreneur in residence, and several principals and associates on the Polaris team. Approach: Seed and revenue stage investing requires active involvement between investors and entrepreneurs. Polaris Venture Partners helps companies by offering operational and investment expertise, identifying and attracting top talent, and assisting in market strategy and business development. The firm looks for exceptional entrepreneurs and a service/product that addresses fast-growing markets with high margins and recurring revenues. Polaris invests throughout key growth periods in order to bring the company to full independence and profitability. It is usually a lead or co-lead investor and serves on the boards of more than 90% of its portfolio companies. Founded: 1996 Headquarters: 1000 Winter Street, Suite 3350, Waltham,
MA 02451 |
| Techno
Venture Management Techno Venture Management (TVM), founded in 1983, is one of the first venture capital funds formed in Germany, and a leader in transatlantic operations. The German-U.S. venture capital company has offices in Munich and Boston. For many years, TVM has focused on information technology and life sciences, high growth sectors where innovation, effective management and sound financial backing have enormous impact on company growth. TVM funds have made investments in 200 technology companies in Europe and the United States. A pivotal objective is to create transnational businesses that enjoy access to science, management talent and capital on both sides of the Atlantic. |
 |
| Transgene Transgene is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic vaccines, immunotherapy and gene therapy products for cancer. Transgene, listed on the Nouveau Marché and the NASDAQ, is based in Strasbourg France and has an office in Boston, MA. Transgene has raised 87.5M Euro on the Nouveau Marché and the NASDAQ in 1998 and 61.4M Euro in 2001. BioMérieux owns 70.3 % of the capital with the remaining held by HGS, CEA, AFM and floating (19,5 %). Transgene has 5 products in development : Transgene masters 4 assets that are key to the research and development of therapeutic vaccines, immunotherapy and gene therapy products for cancer : 1) gene access, gene in vitro and in vivo screening, 2) state of the art multiple vector platform (MVA, adenovirus, synthetic), 3) GMP manufacturing facility for the production of clinical and commercial batches and 4) broad IP portfolio. Transgene’s Business Development focus on 4 major activities : 1) identify partners for the development and commercialization of our Phase I and Phase II programs, 2) in-license genes/targets of therapeutic interest in the field of cancer, 3) enter into technology based agreements on our vectors (MVA, adenovirus and synthetic vectors) and core technology, 4) perform for third parties subcontracting activities for the production of preclinical and clinical batches of adenovirus and MVA based products. Transgene has collaboration with Merck, HGS, IAVI, Aventis, Ajinomoto, AFM (Association Française contre les Myopathies), Mirus, ICRT and Cayla. |
| Vernalis Vernalis is a new force in UK biotechnology, formed
from the merger of British Biotech plc and Vernalis Group plc in
September 2003. It has a product approved and marketed in the US
and Europe, and an innovative development portfolio. Its current
market capitalisation is around $160 million, and it is pursuing
a growth strategy based upon successful pipeline development and
further M&A. |
| Warburg
Pincus International LLC Warburg Pincus has been a leading private equity
investor since 1971. The firm currently has approximately $8 billion
under management and $6 billion available for investments. We take a different approach to investing, beginning with a thorough evaluation of macroeconomic and industry fundamentals. Private equity at Warburg Pincus means investing at all stages of a company’s life cycle: from founding start-ups and fostering growth in developing companies to leading complex recapitalizations or large-scale buyouts of more mature businesses. At the heart of our approach is an emphasis on building sustainable businesses. With an average investment period of five to seven years, we take an unusually long-term perspective. Matched with our size and scope of funds under management, this approach enables the firm to provide substantial resources to our portfolio companies, a critical advantage in the face of constantly changing economic conditions and volatile financial markets. Our people are critical to our success as an experienced partner. Our staff of more than 100 professionals in 9 offices worldwide has expertise in a broad range of sectors. Our 15 dedicated Healthcare/Life Sciences professionals have invested over US$ 3 billion in 100 companies around the world. |
| Womble
Carlyle Sandridge & Rice, PLLC,
Partner Founded in 1876, Womble Carlyle Sandridge &
Rice, PLLC has a 127-year history of helping business leaders address
evolving challenges and uncover new opportunities. While Womble
Carlyle offers a full range of sophisticated legal services, including
intellectual property and biotechnology expertise, the Firm also
has distinguished itself through the innovative use of technology,
both to facilitate the delivery of legal services and to provide
alternative solutions for improving management efficiencies and
profitability. |
| Zero
Stage Capital Founded in 1981, Zero Stage Capital is a venture capital firm that invests in emerging growth companies in the following technology sectors: information technology, communications, life sciences and energy technology. Zero Stage Capital is headquartered in Cambridge, MA and has offices in Manchester, NH, New Haven, CT and Providence, RI and primarily invests in companies located along the east coast of the United States. One of the original pioneers of start-up company investing, Zero Stage Capital proactively invests and manages a balanced and diversified fund investing across technology sectors and across all stages of company growth. Zero Stage Capital seeks to achieve superior returns for its investors, while creating an attractive liquidity profile, by investing approximately 50 percent of its funds in early-stage ventures and 50 percent in later-stage ongoing companies. Since 1994, Zero Stage Capital has performed in the top ten percent among peer funds. With more than 140 years of venture capital, entrepreneurial, operating, and industry experience among its investment professionals, Zero Stage Capital is the lead investor in more than 80 percent of its portfolio company investments. |
|